GS Chowdhary, Kunal Kishore, Sharad Yadav


Background:  Lung cancer is the leading cause of cancer death globally and is now considered as the commonest fatal malignancy in the developed world. India contributes to 20% of all deaths due to lung cancer in the world.

Methods: To study the clinical and paraneoplastic presentations of lung cancer, we carried out a single centre, cross sectional observational study on a cohort of 100 patients of freshly detected Lung cancer.

Results: Mean age of the subjects was 56.36 years and 30% of the cases were above 60 years of age. Majority (63%) of them were males and smokers (59%). Most common presenting symptoms were cough (22.21%), chest pain (16.13%), fever (14.37%), dyspnoea (11%) and hemoptysis (5.22%). Paraneoplastic syndromes comprised of anemia and leucopenia (20%) cases followed CNS manifestation (in 8%) cases. No association was observed between type of lung carcinoma and paraneoplastic syndrome.

Conclusion: Our study confirms the high prevalence of lung cancer in male smokers with predominantly respiratory complaints. Paraneoplastic  syndromes are not a rare entity in such patients and a high level of clinical suspicion is required for early detection of such cases.


Lung cancer, anemia, paraneoplastic, smokers

Full Text:



T Sethi, Lung cancer Introduction, Review series, Thorax 2002;57:992–993

Khuri Fr, Herbst Rs, Fossells FV. Emerging therapies in non small-cell lung cancer. Ann Oncol 2001; 12: 739-44.

West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987–99.

Nath V, Grewal K S. Cancer in India. Ind J Med Res 1935; 23: 149- 190.

Thankappan KR & Thresia CU. Tobacco use & social status in Kerala. Indian J Med Res 2007; 126: 300-308 ( Accessed on 26th November 2011.)

Pai SA. Gutka banned in Indian states. Lancet Oncol 2002; 3: 521.

Murray CJ & Lopez AD (Eds). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, Massachusetts: Harvard School of Public Health; 1996.

Jindal SK, Behera D. Clinical spectrum of primary lung cancer – review of Chandigarh experience of 10 years. Lung India 1990;8:94-98

Noronha V, Dikshit R, Raut N, Joshi A, Pramesh C S, George K, Agarwal J P, Munshi A, Prabhash K. Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience. Indian J Cancer 2012;49:74-8

Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Comparison of Aspects of Smoking Among Four Histologic Types of Lung Cancer. Tob Control 2008; 17(3): 198–204.

Khurana S. Lung cancer. oads/pdf/lungcancer-factsheet.

Tobacco Free Initiative (TFI). World Health Organization. Accessed on 26th November 2011.

Kirmani N, Jamil K, Naidu MUR. Occupational and environmental carcinogens in epidemiology of lung cancer in South Indian population. Biology and Medicine 2010; 2(4): 1-11.

Beckles AM, Spiro SG, Colice GL, Rudd RM. Initial evaluation of patients with lung cancer. Symptoms, signs, laboratory tests and paraneoplastic syndromes. Chest 2003; 123: 975

Sutherland G. Current approaches to the management of smoking cessation. Drugs 2002;62(Suppl 2):53–61

Anderson H A, Prakash UBS. Diagnosis of symptomatic lung cancer. Semin Respir Med 1982; 3:165.

Wilker J D, Fidias, P, Veikers, L, Perer, R P Malignancy related pericardial effusion. 127 cases from the Roswell Park cancer Institute. Cancer 1995; 76:1377

Alberg, AJ; MV; Samet, JM (2016). Chapter 52: Epidemiology of lung cancer.

Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379

World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008

Viswanathan R, Sen Gupta, Iyer PV. Incidence of primary lung cancer in India. Thorax. 1962;17:73–6.

GLOBOCAN 2012 report. Execute .

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

Jindal SK, Behera D. Clinical spectrum of primary lung cancer – Review of Chandigarh experience of 10 years. Lung India. 1990;8:94–8.

Zhong L, Goldberg MS, Parent ME, Hanley JA. Exposure to environmental tobacco smoke and the risk of lung cancer: A meta-analysis. Lung Cancer. 2000;27:3–18.

Gupta D, Aggarwal A, Jindal S. Pulmonary effects of passive smoking: The Indian experience. Tob Induc Dis. 2002;1:129–36.

Krishnamurthy A, Vijayalakshmi R, Gadigi V, Ranganathan R, Sagar TG. The relevance of “nonsmoking-associated lung cancer” in India: A single-centre experience. Indian J Cancer. 2012;49:82–8.

Malik PS, Sharma MC, Mohanti BK, Shukla NK, Deo S, Mohan A, et al. Clinico-pathological profile of lung cancer at AIIMS: A changing paradigm in India. Asian Pac J Cancer Prev. 2013;14:489–94.

V Noronha1, R Dikshit2, N Raut3, A Joshi1, CS Pramesh4, K George4, JP Agarwal5, A Munshi5, K Prabhash1

Rawat J1, Girish S2, Sunil S3 et al. clinico, a pathological profile of the lung cancer in Uttrakhand. 2009

Alamoudi OS et al. aimed to assess the clinical, radiological, pathological, biochemical and bronchoscopic abnormalities in lung cancer patients

Baburao A et al. [3] aimed to evaluate the clinicpathological profile and haematological abnormalities associated with lung cancer in Bangalore, India.

Dubey N et al. [4] aimed to study the risk factors, the time taken to diagnose and the investigations useful in the diagnosis of lung cancer patients

Gupta R et al. [5] aimed to study the clinical features, radiological manifestations and histological types of primary lung carcinoma.

Hafez MR et al. [6] aimed to analyse the clinical, radiological, laboratory, and bronchoscopic findings characterizing each type of bronchogenic carcinoma.

Rana S et al. [7] aimed to study the clinical, radiological, and histopathological profile of endobronchial lesions detected during bronchoscopy.

Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328:1519.

Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.

Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119:3976-3983.

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018 Jul;68(4):297-316.

Wender R, Fontham E, Barrera E, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:106–117.

Neiderhuber JE, Armitage JO, Doroshow JA, Kastan MB, Tepper JE, eds. Cancer of the lung: non–small cell lung cancer and small cell lung cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Saunders; 2013.

Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med 2015; 139:469.

Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8:823.

Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:2078.

Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376:2415.

Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 2013; 159:411.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.

Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974; 65:299.

Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107.

Athey VL, Walters SJ, Rogers TK. Symptoms at lung cancer diagnosis are associated with major differences in prognosis. Thorax 2018; 73:1177.

Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112:440.

Colice GL. Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT. Chest 1997; 111:877.

Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63:695.

Piehler JM, Pairolero PC, Gracey DR, Bernatz PE. Unexplained diaphragmatic paralysis: a harbinger of malignant disease? J Thorac Cardiovasc Surg 1982; 84:861.

Ramadan HH, Wax MK, Avery S. Outcome and changing cause of unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 1998; 118:199.

Chen HC, Jen YM, Wang CH, et al. Etiology of vocal cord paralysis. ORL J Otorhinolaryngol Relat Spec 2007; 69:167.

Decker DA, Dines DE, Payne WS, et al. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest 1978; 74:640.

Maskell NA, Butland RJ, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003; 58 Suppl 2:ii8.

Swiderek J, Morcos S, Donthireddy V, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010; 137:68.

Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. Eur J Radiol 2006; 59:93.

Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 1994; 49:14.

World Health Organization. Cancer. Fact Sheet No 297. January 2013.

Stenbygaard LE, Sørensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung--a study from a cohort of 259 consecutive patients treated with chemotherapy. Acta Oncol 1997; 36:301.

Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483.

Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44:317.

Oliver TW Jr, Bernardino ME, Miller JI, et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984; 153:217.

Pagani JJ. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. AJR Am J Roentgenol 1983; 140:949.

Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007; 242:882.

Doyle TJ. Brain metastasis in the natural history of small-cell lung cancer: 1972-1979. Cancer 1982; 50:752.

Hiraki A, Ueoka H, Takata I, et al. Hypercalcemia-leukocytosis syndrome associated with lung cancer. Lung Cancer 2004; 43:301.

Thomas L, Kwok Y, Edelman MJ. Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol 2004; 5:51.

List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986; 4:1191.

Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010; 68:111.

Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.

Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2:22.

Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.

Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745.

Kosmidis P, Krzakowski M, ECAS Investigators. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 2005; 50:401.

Kasuga I, Makino S, Kiyokawa H, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001; 92:2399.

Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax 2005; 60:1059.

Aoe K, Hiraki A, Ueoka H, et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71:170.

Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23:330.

Ost DE, Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e121S.

Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e142S.

Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e211S.

Mohammed N, Kestin LL, Grills IS, et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79:466.

Ford DW, Koch KA, Ray DE, Selecky PA. Palliative and end-of-life care in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e498S


  • There are currently no refbacks.